

Janne Martikainen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7590686/publications.pdf>

Version: 2024-02-01

40
papers

448
citations

759233

12
h-index

794594

19
g-index

42
all docs

42
docs citations

42
times ranked

839
citing authors

#	ARTICLE	IF	CITATIONS
1	Digitally Supported Lifestyle Intervention to Prevent Type 2 Diabetes Through Healthy Habits: Secondary Analysis of Long-Term User Engagement Trajectories in a Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e31530.	4.3	9
2	Hospital treatment costs associated with incident complications in patients with type 2 diabetes—real-world study based on electronic patient information systems. <i>BMC Health Services Research</i> , 2022, 22, 469.	2.2	1
3	Correlation of the disease-specific Canadian Cardiovascular Society (CCS) classification and health-related quality of life (15D) in coronary artery disease patients. <i>PLoS ONE</i> , 2022, 17, e0266101.	2.5	1
4	Marked Improvement in A1C Levels After Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Maintained Over 4 Years in Patients With Type 1 Diabetes. <i>Diabetes Spectrum</i> , 2022, 35, 469-475.	1.0	3
5	Willingness to Pay for Implementation of an Environmentally Friendly Pharmaceutical Policy in Finland—A Discrete Choice Experiment Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6535.	2.6	6
6	Data-driven long-term glycaemic control trajectories and their associated health and economic outcomes in Finnish patients with incident type 2 diabetes. <i>PLoS ONE</i> , 2022, 17, e0269245.	2.5	0
7	Total cost of care increases significantly from early to mild Alzheimer’s disease: 5-year ALSOVA follow-up. <i>Age and Ageing</i> , 2021, 50, 2116-2122.	1.6	6
8	Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis. <i>BMC Health Services Research</i> , 2021, 21, 916.	2.2	2
9	Comparison of Communication Channels for Large-Scale Type 2 Diabetes Risk Screening and Intervention Recruitment: Empirical Study. <i>JMIR Diabetes</i> , 2021, 6, e21356.	1.9	5
10	Cost-effectiveness of physical activity intervention in children—results based on the Physical Activity and Nutrition in Children (PANIC) study. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2021, 18, 116.	4.6	2
11	Type 2 Diabetes-Related Health Economic Impact Associated with Increased Whole Grains Consumption among Adults in Finland. <i>Nutrients</i> , 2021, 13, 3583.	4.1	11
12	Digitalization as an Engine for Change? Building a Vision Pathway towards a Sustainable Health Care System by Using the MLP and Health Economic Decision Modelling. <i>Sustainability</i> , 2021, 13, 13007.	3.2	3
13	Attitudes and Considerations towards Pharmaceuticals-Related Environmental Issues among Finnish Population. <i>Sustainability</i> , 2021, 13, 12930.	3.2	8
14	Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 81-88.	1.9	1
15	Short-term impact of co-payment level increase on the use of medication and patient-reported outcomes in Finnish patients with type 2 diabetes. <i>Health Policy</i> , 2020, 124, 1310-1316.	3.0	6
16	Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes. <i>BMC Health Services Research</i> , 2020, 20, 1095.	2.2	6
17	Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5L index scores in the Finnish population. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 117.	2.4	12
18	Digitally supported program for type 2 diabetes risk identification and risk reduction in real-world setting: protocol for the StopDia model and randomized controlled trial. <i>BMC Public Health</i> , 2019, 19, 255.	2.9	24

#	ARTICLE	IF	CITATIONS
19	<p></p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 159-168.	1.9	10
20	The effects of reimbursement reform of antidiabetic medicines from the patients' perspective – a survey among patients with type 2 diabetes in Finland. BMC Health Services Research, 2019, 19, 769.	2.2	8
21	Long-term medical costs of Alzheimer's disease: matched cohort analysis. European Journal of Health Economics, 2019, 20, 333-342.	2.8	14
22	The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. Journal of Alzheimer's Disease, 2018, 61, 1367-1376.	2.6	24
23	Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 47-57.	2.7	57
24	Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Effectiveness and Resource Allocation, 2018, 16, 56.	1.5	9
25	Does routinely collected patient-reported outcome data represent the actual case-mix of elective coronary revascularization patients?. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 113-119.	4.0	5
26	Health-related quality of life in relation to symptomatic and radiographic definitions of knee osteoarthritis: data from Osteoarthritis Initiative (OAI) 4-year follow-up study. Health and Quality of Life Outcomes, 2018, 16, 154.	2.4	21
27	Entitlement of carer's allowance to support home care of persons with Alzheimer's disease: evaluation of current decision criteria. European Geriatric Medicine, 2018, 9, 477-483.	2.8	3
28	Body size at birth and coronary heart disease-related hospital care in adult men – findings from the Helsinki Birth Cohort Study. Annals of Medicine, 2017, 49, 126-133.	3.8	1
29	Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study. International Psychogeriatrics, 2017, 29, 1723-1733.	1.0	15
30	Targeted identification of adverse events in coronary artery disease patients based on patient-reported outcomes. Journal of Comparative Effectiveness Research, 2017, 6, 583-589.	1.4	1
31	Does Future Diabetes Risk Impair Current Quality of Life? A Cross-Sectional Study of Health-Related Quality of Life in Relation to the Finnish Diabetes Risk Score (FINDRISC). PLoS ONE, 2016, 11, e0147898.	2.5	11
32	Socioeconomic Inequalities in Statin Adherence Under Universal Coverage. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 704-713.	2.2	32
33	The coverage of elective revascularisation procedure codes in the National Finnish Hospital Discharge Register. Annals of Medicine, 2016, 48, 552-558.	3.8	0
34	Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers' well-being: ALSOVA 3-year follow-up. International Journal of Geriatric Psychiatry, 2016, 31, 273-283.	2.7	32
35	Comparison of EQ-5D and 15D instruments for assessing the health-related quality of life in cardiac surgery patients. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 193-200.	4.0	17
36	Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence – Estimates from the Finnish prescription register. Atherosclerosis, 2015, 239, 240-247.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Depressive Symptoms Are Associated with Analgesic Use in People with Alzheimer's Disease: Kuopio ALSOVA Study. PLoS ONE, 2015, 10, e0117926.	2.5	11
38	Decreasing sense of coherence and its determinants in spousal caregivers of persons with mild Alzheimer's disease in three year follow-up: ALSOVA study. International Psychogeriatrics, 2014, 26, 1211-1220.	1.0	18
39	Quality of life along the diabetes continuum: a cross-sectional view of health-related quality of life and general health status in middle-aged and older Finns. Quality of Life Research, 2014, 23, 1935-1944.	3.1	31
40	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 494-508.	1.3	5